Guggenheim Securities Initiates Coverage on Theravance Biopharma Inc(NASDAQ:TBPH). The shares have been rated Buy. The rating by Guggenheim Securities was issued on Jun 20, 2016.
In a different note, On May 5, 2016, Bank of America said it Downgrades its rating on Theravance Biopharma Inc. The shares have been rated ‘Neutral’ by the firm.
Theravance Biopharma Inc (TBPH) shares turned negative on Fridays trading session with the shares closing down -0.48 points or -2.08% at a volume of 13,66,843. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $22.87. The peak price level was also seen at $22.87 while the days lowest was $22.1. Finally the shares closed at $22.58. The 52-week high of the shares is $24.76 while the 52-week low is $10.56. According to the latest information available, the market cap of the company is $1,072 M.
Theravance Biopharma Inc(TBPH) last announced its earnings results on May 9, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $18.41M. Analysts had an estimated revenue of $18.69M. Earnings per share were $-1.10. Analysts had estimated an EPS of $-1.03.
Several Insider Transactions has been reported to the SEC. On Mar 15, 2016, Plc Glaxosmithkline (10% owner) purchased 1,301,015 shares at $17.70 per share price.Also, On Aug 18, 2015, Junning Lee (Sr. VP, Technical Operations) purchased 9,000 shares at $12.90 per share price.On Aug 18, 2015, Burton G Malkiel (director) purchased 10,000 shares at $12.92 per share price, according to the Form-4 filing with the securities and exchange commission.
Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets and a productive research platform designed for long-term growth. VIBATIV (telavancin) its commercial product is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.